A quantitative key-opinion-leader analysis of innovation barriers in probiotic research and development: Valorisation and improving the tech transfer cycle

Nieuwboer, M. van den; Burgwal, Linda van de; Claassen, Eric

doi:10.1016/j.phanu.2015.09.003

Cited by 55 publications

(68 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Agenda-setting is an often overlooked-but essential-step in addressing unmet needs via research and innovation. 9 A neglect of specific medical, societal, or technical unmet needs may therefore hinder innovative progress, a case which has been exemplified by the increased budget the US Congress allocated for GHSA initiatives and the simultaneous decrease in budgets for research on pathogenesis and epidemiology. 7 Heterogeneities in unmet need profiles of different institution types likely resulted in such articulation mismatch in the field of Ebola, contributing to the lack of medical preparedness.…”

Section: Figurementioning

confidence: 99%

Self-Centric and Altruistic Unmet Needs for Ebola: Barriers to International Preparedness

Burgwal

Reperant

Osterhaus

et al. 2016

Disaster med. public health prep.

View full text Add to dashboard Cite

show abstract

Section: Figurementioning

confidence: 99%

Self-Centric and Altruistic Unmet Needs for Ebola: Barriers to International Preparedness

Burgwal

Reperant

Osterhaus

et al. 2016

Disaster med. public health prep.

View full text Add to dashboard Cite

show abstract

“…This study shows that the rabies field is not insensitive to common valorization barriers and that steps between domains are often skipped. Stakeholders from some domains act within their own discourse without being connected to other domains, as was shown before for other fields of public health (Claassen, 2014;Pronker, 2013;Van Den Nieuwboer, Van De Burgwal, & Claassen, 2016). This becomes especially evident from the limited number of innovations that are successfully transferred from the science to the business domain ( Figure 4: 10c and 12a).…”

Section: Discussionmentioning

confidence: 76%

Barriers to innovation in human rabies prophylaxis and treatment: A causal analysis of insights from key opinion leaders and literature

Burgwal

Neevel

Pittens

et al. 2017

Zoonoses and Public Health

Self Cite

View full text Add to dashboard Cite

SummaryRabies is an essentially 100% fatal, zoonotic disease, caused by Lyssaviruses. Currently, the disease is vaccine-preventable with pre-and post-exposure prophylaxis (PrEP and PEP). Still, rabies virus is estimated to cause up to 60,000 human deaths annually, of which the vast majority occurs in rural Asia and Africa, due to the inaccessibility of prophylaxis and non-existence of treatment. Despite these unmet clinical needs, rabies control mainly focuses on the sylvatic reservoir and drug innovation receives relatively little attention compared to other neglected tropical diseases (NTDs). As such, the lag of innovation in human rabies prophylaxis and treatment cannot be explained by limited return on investment alone. Strategies countering rabies-specific innovation barriers are important for the acceleration of innovation in human rabies prophylaxis and treatment. Barriers throughout society, science, business development and market domains were identified through literature review and 23 semi-structured interviews with key opinion leaders worldwide. A subsequent root cause analysis revealed causal relations between innovation barriers and a limited set of root causes. Finally, prioritization by experts indicated their relative importance. Root causes, which are fundamental to barriers, were aggregated into four types: market and commercial, stakeholder collaboration, public health and awareness, and disease trajectory. These were found in all domains of the innovation process and thus are relevant for all stakeholders. This study identifies barriers that were not previously described in this specific context, for example the competition for funding between medical and veterinary approaches. The results stress the existence of barriers beyond the limited return on investment and thereby explain why innovation in human rabies medication is lagging behind NTDs with a lower burden of disease. A re-orientation on the full spectrum of barriers that hinder innovation in rabies prophylaxis and treatment is necessary to meet unmet societal and medical needs. K E Y W O R D Sbarriers, preventive medicine, public health, rabies, root cause analysis, treatment of diseases † These authors contributed equally to this work.This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

“…This study takes qualitative [ 28 , 29 ] and semi-quantitative approaches to identify and prioritize ownership barriers for the sharing of MGR and to understand in-depth how these barriers influence sharing in the system of practice. To this purpose, interviews were performed with key experts in the field and a root-cause analysis was conducted to analyze the interrelations of barriers and their impact on innovation processes and infectious disease control [ 30 ].…”

Section: Methodsmentioning

confidence: 99%

How ownership rights over microorganisms affect infectious disease control and innovation: A root-cause analysis of barriers to data sharing as experienced by key stakeholders

Ribeiro

Roode²,

Haringhuizen

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

BackgroundGenetic information of pathogens is an essential input for infectious disease control, public health and for research. Efficiency in preventing and responding to global outbreaks relies on timely access to such information. Still, ownership barriers stand in the way of timely sharing of genetic data from pathogens, frustrating efficient public health responses and ultimately the potential use of such resources in innovations. Under a One Health approach, stakeholders, their interests and ownership issues are manifold and need to be investigated. We interviewed key actors from governmental and non-governmental bodies to identify overlapping and conflicting interests, and the overall challenges for sharing pathogen data, to provide essential inputs to the further development of political and practical strategies for improved data sharing practices.Methods & findingsTo identify and prioritize barriers, 52 Key Opinion Leaders were interviewed. A root-cause analysis was performed to identify causal relations between barriers. Finally, barriers were mapped to the innovation cycle reflecting how they affect the range of surveillance, innovation, and sharing activities. Four main barrier categories were found: compliance to regulations, negative consequences, self-interest, and insufficient incentives for compliance. When grouped in sectors (research institutes, public health organizations, supra-national organizations and industry) stakeholders appear to have similar interests, more than when grouped in domains (human, veterinary and food). Considering the innovation process, most of barriers could be mapped to the initial stages of the innovation cycle as sampling and sequencing phases. These are stages of primary importance to outbreak control and public health response. A minority of barriers applied to later stages in the innovation cycle, which are of more importance to product development.ConclusionOverall, barriers are complex and entangled, due to the diversity of causal factors and their crosscutting features. Therefore, barriers must be addressed in a comprehensive and integrated manner. Stakeholders have different interests highlighting the diversity in motivations for sharing pathogen data: prioritization of public health, basic research, economic welfare and/or innovative capacity. Broad inter-sectorial discussions should start with the alignment of these interests within sectors. The improved sharing of pathogen data, especially in upstream phases of the innovation process, will generate substantial public health benefits through increased availability of data to inform surveillance systems, as well as to allow the (re-)use of data for the development of medical countermeasures to control infectious diseases.

show abstract

A quantitative key-opinion-leader analysis of innovation barriers in probiotic research and development: Valorisation and improving the tech transfer cycle

Cited by 55 publications

References 27 publications

Self-Centric and Altruistic Unmet Needs for Ebola: Barriers to International Preparedness

Self-Centric and Altruistic Unmet Needs for Ebola: Barriers to International Preparedness

Barriers to innovation in human rabies prophylaxis and treatment: A causal analysis of insights from key opinion leaders and literature

How ownership rights over microorganisms affect infectious disease control and innovation: A root-cause analysis of barriers to data sharing as experienced by key stakeholders

Contact Info

Product

Resources

About